Key result
Liposomal co-encapsulation of curcumin and doxorubicin improved the pharmacokinetics and biodistribution of doxorubicin, limiting its side effects via curcumin-dependent antioxidant effects.
Why the study?
To investigate the pharmacokinetic profile, tissue distribution, and adverse effects of long-circulating liposomes with curcumin and doxorubicin, seeking further evidence for previously demonstrated antitumor efficacy.
Does liposomal co-encapsulation of doxorubicin with curcumin improve pharmacokinetics and reduce adverse effects in rodent models?
Does liposomal co-encapsulation of doxorubicin with curcumin improve pharmacokinetics and reduce adverse effects in rodent models?
Co-encapsulation of doxorubicin and curcumin in long-circulating liposomes improves pharmacokinetics and reduces cardiac and hepatic oxidative side effects in preclinical models.
Hypothesis-generating in rodent models; leaves open clinical translation for reduced doxorubicin cardiotoxicity.
The goal of the current study was to investigate the pharmacokinetic profile, tissue distribution and adverse effects of long-circulating liposomes (LCL) with curcumin (CURC) and doxorubicin (DOX), in order to provide further evidence for previously demonstrated enhanced antitumor efficacy in colon cancer models. The pharmacokinetic studies were carried out in healthy rats, following the i.v. injection of a single dose of LCL-CURC-DOX (1 mg/kg DOX). For the tissue distribution study, DOX concentration in tumours, heart and liver were measured after the administration of two i.v. doses of LCL-CURC-DOX (2.5 mg/kg DOX and 5 mg/kg CURC) to Balb/c mice bearing C26 colon tumours. Markers of murine cardiac and hepatic oxidative status were determined to provide additional insights into the benefit of co-encapsulating CURC and DOX in LCL over DOX-induced adverse effects in these organs. The current study demonstrated that the liposomal association of CURC and DOX effectively improved the pharmacokinetics and biodistribution of DOX, limiting its side effects, via CURC-dependent antioxidant effects.
No takes yet. Share an insight, caveat, or question.
Sesărman et al. (2019) studied Healthy rats and Balb/c mice bearing C26 colon tumours. Long-circulating liposomes (LCL) with curcumin (CURC) and doxorubicin (DOX) was evaluated on Pharmacokinetic profile, tissue distribution, and adverse effects (cardiac and hepatic oxidative status). Liposomal co-encapsulation of curcumin and doxorubicin improved the pharmacokinetics and biodistribution of doxorubicin, limiting its side effects via curcumin-dependent antioxidant effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: